Week In Review: Everest Announces Two In-Licensings With Total Value Of $1 Billion

Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Suzhou Sinovent and SinoMab Bio in a $561 million deal. Shanghai Everest Medicines announced a $500 million two-part deal with Providence Therapeutics for mRNA products.